Compare · DXCM vs INSP
DXCM vs INSP
Side-by-side comparison of DexCom Inc. (DXCM) and Inspire Medical Systems Inc. (INSP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and INSP operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 16.3x INSP ($2.03B).
- INSP has been more active in the news (8 items in the past 4 weeks vs 6 for DXCM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Inspire Medical Systems Inc.
- Price
- -
- -
- Market cap
- $33.10B
- $2.03B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- 2018
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Inspire Medical Systems Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest INSP
- SEC Form 4 filed by Inspire Medical Systems Inc.
- SEC Form 4 filed by Inspire Medical Systems Inc.
- SEC Form 4 filed by Inspire Medical Systems Inc.
- SEC Form 4 filed by Inspire Medical Systems Inc.
- Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
- Barclays initiated coverage on Inspire Medical Systems with a new price target
- Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026
- Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
- Officer Kelly Jason P was granted 6,350 shares, increasing direct ownership by 33% to 25,335 units (SEC Form 4)
- Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference